Introduction {#s1}
============

Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide and it is estimated that nearly 500,000 cases are diagnosed annually worldwide (Antoni et al., [@B1]). Despite improvements in current clinical treatment such as surgery, radiation therapy, and chemotherapy, 50--70% of patients are relapsed within the next 5 years (Terracciano et al., [@B32]). Therefore, it is urgent to find novel markers for diagnosis at early stage and identify effective therapeutic targets for improving the survival rate of patients with bladder cancer.

Long non-coding RNAs (lncRNAs) are generally defined as RNA transcripts longer than 200 nucleotides that lack an open reading frame. Recently, increasing evidences show that lncRNAs play important roles in various cancers, which influence all the "hallmarks of cancer" (Gutschner and Diederichs, [@B15]). It is reported that lncRNAs are involved in various cell biological processes, such as tumor cell proliferation, apoptosis, invasion, and metastasis (Hansji et al., [@B16]; Terracciano et al., [@B32]). So the aberrant expression patterns of lncRNAs are correlated with cancer diagnosis and prognosis and serve as predictors of patient outcomes. For example, LncRNA H19 expression was up-regulated and closely related to TNM cancer stages in patients with gastric cancer, which can serve as a potential non-invasive diagnostic biomarker in gastric cancer (Hashad et al., [@B17]). Sun et al. ([@B31]) indicated that the lncRNA antisense non-coding RNA in the INK4 locus (ANRIL) was up-regulated in colorectal cancer tissues, which was associated with the survival rate of patients with colorectal cancer. LncRNA-activated by TGF-β (lncRNA-ATB) was significantly up-regulated in hepatocellular carcinoma metastases and associated with poor prognosis (Yuan et al., [@B46]).

Up to now, it was reported that some lncRNAs was aberrantly expressed in bladder cancer, such as HULC (Wang J. et al., [@B36]), MALAT1 (Li et al., [@B24]), and SNHG16 (Cao et al., [@B2]). Hu R. G. et al. ([@B21]) found that the lncRNA cancer susceptibility candidate 8 (CASC8) was significantly down-regulated in bladder cancers and associated with the advanced stage of bladder cancer patients, overexpression of which remarkably suppressed the bladder cancer cell proliferation. Hepatocellular carcinoma up-regulated long non-coding RNA (HULC) promoted bladder cancer cells proliferation and inhibited apoptosis via regulation of ZIC2 and PI3K/AKT signaling pathway (Wang J. et al., [@B36]). LncRNA urothelial cancer-associated 1 (UCA1) promoted bladder cancer cell migration and invasion via hsa-miR-145/ZEB1/2/FSCN1 pathway (Xue et al., [@B42]). Recently several studies have investigated the prognostic and diagnostic value of lncRNAs in bladder cancer. However, most studies examining the clinical values of aberrantly expressed lncRNAs was limited by the small sample size or a single lncRNA. Therefore, we conducted a systematic review and meta-analysis to evaluate the clinicopathological, prognostic, and diagnostic roles of multiple lncRNAs expression in patients with bladder cancer.

Methods {#s2}
=======

Publication search
------------------

The present systematic review was performed according to the PRISMA Statement (Moher et al., [@B29]) (see Table [S1](#SM1){ref-type="supplementary-material"} PRISMA Checklist) and Cochrane Collaboration guidelines (<http://handbook.cochrane.org/>). We searched the Pubmed, Embase and Web of Science to identify relevant studies until December 21, 2017. The search strategies were based on combinations of the following key words: ("long non-coding RNA," "lncRNA," "lincRNA," "long ncRNA," "long intergenic non-coding RNA") AND ("bladder") AND ("cancer," "carcinoma," "neoplasm," "tumor," "tumors," "tumor," "tumors," "malignancy," "metastasis"). In addition, the references of eligible studies and relevant systematic reviews were checked for other eligible studies. We provided the detailed search strategies and results in the Table [S2](#SM2){ref-type="supplementary-material"}.

Selection criteria
------------------

The included studies met the following criteria: (1) patients in the study were diagnosed with bladder cancer; (2) studies investigated the association between lncRNAs and bladder cancer; (3) sample size was no less than 40 cases; (4) for clinicopathological studies, the correlation between lncRNAs and clinicopathological parameters of patients with bladder cancer was performed, and the expression level of lncRNAs was divided into high or low groups; (5) for prognostic studies, the correlation between lncRNAs and survival was performed and the primary endpoints as overall survival (OS), disease free survival (DFS), cancer-specific survival (CSS) or recurrence-free survival (RFS) were clearly defined, then Kaplan--Meier survival curves or sufficient original data was provided to extract hazard ratio (HR) with 95% confidence interval (CI); (6) for diagnostic studies, diagnostic accuracy of lncRNAs for bladder cancer was performed, and sufficient data was provided for constructing the diagnostic two-by-two tables.

The exclusion criteria were: (1) overlapping or duplicate data; (2) lack of essential information; (3) letter, review article, case report, and conference abstract; and (4) non-English papers and non-human studies.

Data quality assessment and extraction
--------------------------------------

Data were extracted by two authors independently from included studies using a predefined data extraction form. Then another author verified them and any discrepancies were resolved by consensus. The following information were collected: (1) basic information: first author\'s name, publication year, country, study design, patient population, lncRNAs, expression, sample size, tumor type, detected sample, detection method, and cutoff value; (2) clinicopathological parameters: gender, age, tumor size, tumor number, histological grade, TNM stage, tumor stage T, and lymph node metastasis; (3) prognostic information: follow-up months, outcome of survival analysis, and HR with corresponding 95% CI; (4) diagnostic information: sensitivity, specificity, area under the curve (AUC), sample sizes for diagnostic analysis, and data for two-by-two tables \[true positive (TP), false positive (FP), true negative (TN), and false negative (FN)\]. For studies that showed only Kaplan-Meier survival curve, HR with their 95% CI was calculated by using Engauge Digitizer version 4.1 and Tierney\'s method (Tierney et al., [@B34]).

We assessed the methodological quality of prognostic studies using the Newcastle-Ottawa Scale (NOS) tool that was extracted and modified from previous studies (Gao et al., [@B13]). The NOS scores ranged from 0 to 8, and a study with the higher scores indicated better methodological quality. Moreover, the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) list was used to systematically assess the quality of all the included diagnostic studies (Whiting et al., [@B39]). Fourteen items from the QUADAS list were applied to each article, with an answer of "yes," "no," or "unclear." The answer "yes" obtained a score of 1, whereas "no" or "unclear" gained a score of 0, and the full score was 14. If a cumulative score is higher than 8, the study will be considered as low risk of bias.

Statistical analysis
--------------------

Heterogeneity among the included studies was assessed by using the Cochrane\'s *Q*-test and *I*~2~ statistics. If heterogeneity (*p* \< 0.05 or *I*~2~ \> 50%) was statistically significant among studies, the random-effect model was chosen for the meta-analysis; otherwise, the fixed-effect model was used. Odds ratio (OR) with 95% CI was used to evaluate association between lncRNAs expression and clinicopathological parameters. Pooled HR with 95% CI was calculated to summarize the effect between lncRNAs and survival in patients with bladder cancer. For the diagnostic meta-analysis, correlated diagnostic accuracy indexes were computed as follows: sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), summary receiver operating characteristic (SROC) curve, and AUC. Publication bias was detected using Deeks\' regression test of asymmetry (Deeks et al., [@B6]). All statistical analyses were performed by using STATA 13.1 program (Stata Corpotion, College Station, Texas, USA).

Results {#s3}
=======

Study selection
---------------

As shown in the flow diagram (Figure [1](#F1){ref-type="fig"}), we identified 737 records in the electronic databases, including Pubmed, Embase, and Web of Science. Firstly, 283 duplicate records were excluded using EndNote X8. With the inclusion and exclusion criteria, 396 records were excluded by reviewing titles and abstracts. Subsequently, the 58 remaining full-text articles were assessed. Among 58 articles, 21 were excluded from the quantitative synthesis for the reasons depicted in Figure [1](#F1){ref-type="fig"}. No additional studies were identified by a manual search of the references of the original studies. Finally, the remaining 37 articles were eligible for the systematic review (Wang et al., [@B37]; He et al., [@B20], [@B18],[@B19]; Fan et al., [@B12]; Li et al., [@B25], [@B24]; Srivastava et al., [@B30]; Yan et al., [@B43]; Chen et al., [@B4], [@B3]; Eissa et al., [@B10],[@B11]; Milowich et al., [@B28]; Zhao F. J. et al., [@B53]; Zhao X. L. et al., [@B54]; Duan et al., [@B8]; Iliev et al., [@B23]; Zhan et al., [@B47],[@B48], [@B49],[@B50]; Zhang et al., [@B52], [@B51]; Cao et al., [@B2]; Cui et al., [@B5]; Dudek et al., [@B9]; Du et al., [@B7]; Hu Y. Y. et al., [@B22]; Liao et al., [@B26]; Lin et al., [@B27]; Tolkach et al., [@B35]; Wu et al., [@B40]; Xiong et al., [@B41]; Yang et al., [@B44]; Ye et al., [@B45]; Zhuang et al., [@B56]), including 26 studies for clinicopathological parameters, 19 studies for prognosis, and 7 studies for diagnosis.

![Flow diagram of study selection process. lncRNAs, long non-coding RNAs; OS, overall survival; DFS, disease free survival; CSS, cancer-specific survival; RFS, recurrence-free survival.](fphys-09-00652-g0001){#F1}

Clinicopathological parameters
------------------------------

Table [1](#T1){ref-type="table"} summarized the main characteristics of studies on the association between lncRNAs and clinicopathological parameters. All the selected studies on clinicopathological parameters were from China, with 20/26 (76.9%) being published between 2016 and 2017. The systematic review of clinicopathological parameters was performed in 1,896 patients with bladder cancer, including urinary bladder cancer, urothelial carcinoma of the bladder, muscle-invasive bladder cancer, bladder transitional cell carcinomas, and non-muscle invasive bladder cancer. Twenty-four lncRNAs were described in the 26 studies involved in clinicopathological parameters. The expression of MALAT1 (Fan et al., [@B12]; Li et al., [@B24]), ASAP1-IT1 (Yang et al., [@B44]), SPRY4-IT1 (Zhao X. L. et al., [@B54]), lncRNA-n336928 (Chen et al., [@B4]), linc-UBC1 (He et al., [@B20]), SUMO1P3 (Zhan et al., [@B48]), HNF1A-AS1 (Zhan et al., [@B50]), CCEPR (Zhan et al., [@B49]), linc00346 (Ye et al., [@B45]), XIST (Hu Y. Y. et al., [@B22]; Xiong et al., [@B41]), ZEB2-AS1 (Wu et al., [@B40]), ZEB1-AS1 (Lin et al., [@B27]), PVT1 (Cui et al., [@B5]), ABHD11-AS1 (Chen et al., [@B3]), SNHG16 (Cao et al., [@B2]), lncRNA-UNMIBC (Zhang et al., [@B52]), PANDAR (Zhan et al., [@B47]), AATBC (Zhao F. J. et al., [@B53]), and HOTAIR (Yan et al., [@B43]) were up-regulated in bladder cancer patients, while the expression of lncRNA-LET (Zhuang et al., [@B56]), lncRNA-LOWEG (Liao et al., [@B26]), NBAT1 (Du et al., [@B7]), BANCR (He et al., [@B19]), and MIR31HG (He et al., [@B18]) were down-regulated. Only one study reported that down-regulated lncRNA-LOWEG were significantly associated with gender of patients (Liao et al., [@B26]). The results of these studies indicated that 24 lncRNAs were not significantly correlated with age of patients and tumor number. Two studies claimed that up-regulated ZEB2-AS1 (Wu et al., [@B40]) and XIST (Hu Y. Y. et al., [@B22]) were significantly related to tumor size. Dysregulated SPRY4-IT1 (Zhao X. L. et al., [@B54]), lncRNA-n336928 (Chen et al., [@B4]), SUMO1P3 (Zhan et al., [@B48]), HNF1A-AS1 (Zhan et al., [@B50]), CCEPR (Zhan et al., [@B49]), ZEB1-AS1 (Lin et al., [@B27]), NBAT1 (Du et al., [@B7]), PVT1 (Cui et al., [@B5]), ABHD11-AS1 (Chen et al., [@B3]), PANDAR (Zhan et al., [@B47]), AATBC (Zhao F. J. et al., [@B53]), and HOTAIR (Yan et al., [@B43]) were significantly associated with histological grade. Dysregulated ASAP1-IT1 (Yang et al., [@B44]), lncRNA-LET (Zhuang et al., [@B56]), XIST (Hu Y. Y. et al., [@B22]; Xiong et al., [@B41]), ABHD11-AS1 (Chen et al., [@B3]), SNHG16 (Cao et al., [@B2]), BANCR (He et al., [@B19]), and MIR31HG (He et al., [@B18]) were significantly associated with TNM stage. Furthermore, SPRY4-IT1 (Zhao X. L. et al., [@B54]), MALAT1 (Li et al., [@B24]), linc-UBC1 (He et al., [@B20]), lncRNA-LET (Zhuang et al., [@B56]), ZEB2-AS1 (Wu et al., [@B40]), XIST (Hu Y. Y. et al., [@B22]), PVT1 (Cui et al., [@B5]), and SNHG16 (Cao et al., [@B2]) were significantly associated with lymph node metastasis status in patients with bladder cancer.

###### 

Summary of the comparison for the *p*-values of the association between lncRNAs and clinicopathological parameters.

  **Study**   **Year**   **Country**   **Study design**   **Patient population**   **TNM stage**   **Treatment of patient**                                                        **LncRNAs**      **Expression**   **Case number**   **Cutoff**    ***p*****-values**                                                          
  ----------- ---------- ------------- ------------------ ------------------------ --------------- ------------------------------------------------------------------------------- ---------------- ---------------- ----------------- ------------- -------------------- -------- -------- -------- --------- ------- --------- ---------
  Yang L      2017       China         RCS                UBC                      I-IV            Radical cystectomy                                                              ASAP1-IT1        Up               58                Median        1.000                0.790    NA       0.150    NA        0.017   0.014     0.160
  Li C        2017       China         PCS                BC                       NA              Transurethral resection of bladder tumor and radical resection of the bladder   MALAT1           Up               120               Mean          0.769                0.841    0.607    0.755    0.023     NA      0.004     0.009
  Zhuang J    2017       China         PCS                UBC                      0-IV            Surgery                                                                         lncRNA-LET       Down             60                Median        0.146                0.267    NA       0.399    0.424     0.039   NA        0.012
  Zhan YH     2017       China         CCS                UCB                      NA              Radical or partial cystectomy                                                   HNF1A-AS1        Up               79                Fold-change   0.915                0.597    0.081    0.076    0.008     NA      0.034     0.651
  Zhan YH     2017       China         CCS                UCB                      NA              Radical or partial cystectomy                                                   CCEPR            Up               55                Fold-change   0.677                0.473    0.768    0.087    0.021     NA      0.014     NA
  Ye T        2017       China         CCS                BC                       NA              Surgical resection                                                              linc00346        Up               52                NA            0.075                0.634    NA       NA       0.910     NA      0.894     NA
  Xiong YY    2017       China         CCS                BC                       I-IV            Surgical resection                                                              XIST             Up               67                NA            NA                   0.273    0.067    0.901    0.784     0.036   NA        NA
  Wu X        2017       China         CCS                BC                       NA              Curative resection                                                              ZEB2-AS1         Up               52                NA            0.931                0.337    0.023    NA       NA        NA      0.026     0.048
  Lin JH      2017       China         CCS                BC                       NA              NA                                                                              ZEB1-AS1         Up               55                Fold-change   0.792                0.745    0.940    0.197    0.001     NA      0.027     1.000
  Liao XH     2017       China         CCS                UNB                      0-IV            Radical cystectomy                                                              lncRNA-LOWEG     Down             55                Relative      0.04                 0.58     0.97     NA       0.60      0.18    NA        0.63
  Hu YY       2017       China         PCS                BC                       I-IV            Resection surgery                                                               XIST             Up               52                Fold-change   0.658                0.540    0.028    0.425    0.036     0.012   NA        0.042
  Du D        2017       China         RCS                BC                       NA              Surgical resection                                                              NBAT1            Down             79                Fold-change   0.580                0.807    0.179    NA       0.043     NA      0.027     0.073
  Cui Y       2017       China         PCS                BC                       NA              Surgery                                                                         PVT1             Up               146               Mean          0.86                 0.31     0.19     0.72     0.02      NA      0.03      \<0.01
  Chen MW     2017       China         CCS                UC                       0-IV            NA                                                                              ABHD11-AS1       Up               66                Fold-change   0.575                0.587    NA       NA       \<0.001   0.001   0.001     0.663
  Cao X       2017       China         PCS                BC                       0-IV            Total or partial removal of bladder                                             SNHG16           Up               46                Mean          1.000                0.568    NA       NA       NA        0.003   1.000     0.000
  He AB       2016       China         CCS                BC                       0-IV            Surgical resection                                                              MIR31HG          Down             55                NA            0.415                0.607    0.109    NA       0.415     0.010   NA        0.114
  Zhan YH     2016       China         CCS                UBC                      NA              Radical resections                                                              SUMO1P3          Up               55                Fold-change   0.528                0.580    0.114    0.054    0.005     NA      0.037     0.618
  Zhang SM    2016       China         PCS                NMIBC                    NA              NA                                                                              lncRNA-UNMIBC    Up               75                Fold-change   0.4456               0.9851   0.0712   0.0931   0.0725    NA      0.9652    NA
  Zhan YH     2016       China         CCS                UCB                      NA              Partial or radical cystectomy                                                   PANDAR           Up               55                Fold-change   0.953                0.745    0.061    0.759    0.010     NA      0.027     0.607
  He AB       2016       China         CCS                UNB                      0-IV            Radical cystectomy                                                              BANCR            Down             54                Relative      0.09                 0.230    0.065    NA       0.194     0.004   NA        0.559
  Zhao XL     2015       China         PCS                UCB                      NA              Transurethral resection, partial cystectomy and radical cystectomy              SPRY4-IT1        Up               68                Mean          0.707                0.790    0.874    0.813    \<0.001   NA      0.017     \<0.001
  Chen T      2015       China         PCS                BC                       NA              Radical cystectomy                                                              lncRNA-n336928   Up               95                Fold-change   0.479                0.656    0.825    0.307    0.002     NA      \<0.001   NA
  Zhao FJ     2015       China         CCS                BC                       NA              Cystectomy                                                                      AATBC            Up               90                Fold-change   0.899                0.863    NA       NA       0.010     NA      0.015     0.315
  Fan Y       2014       China         RCS                BT                       NA              NA                                                                              MALAT1           Up               95                Median        0.315                0.237    0.213    NA       0.097     NA      0.104     0.063
  Yan TH      2014       China         PCS                BC                       NA              Transurethral resection of the bladder                                          HOTAIR           Up               110               Mean          \>0.05               \>0.05   \>0.05   NA       0.031     NA      \>0.05    NA
  He W        2013       China         RCS                BC                       NA              Surgical resection                                                              linc-UBC1        Up               102               Fold-change   0.655                0.961    NA       NA       0.828     NA      0.422     0.021

*RCS, retrospective cohort study; PCS, prospective cohort study; CCS, case-control study; UBC, urinary bladder cancer; UCB, urothelial carcinoma of the bladder; MIBC, muscle-invasive bladder cancer; BTCC, bladder transitional cell carcinomas; BC, bladder cancer; UNB, urothelial neoplasms of the bladder; UC, urothelial cancer; NMIBC, non-muscle invasive bladder cancer; BT, bladder tumors; LncRNAs, long non-coding RNAs; Up, up-regulation; Down, down-regulation; NA, not available*.

Two lncRNAs (MALAT1 and XIST) were investigated in two studies, respectively. Therefore, we performed a meta-analysis to evaluate the association between MALAT1 and XIST and clinicopathological parameters. For the MALAT1, we combined two studies with a total of three groups according to different clinicopathological parameters (Figure [2](#F2){ref-type="fig"}). Heterogeneity was observed in two groups (Gender, *I*~2~ = 81.0%, *p* = 0.022; Tumor stage T, *I*~2~ = 50.8%, *p* = 0.154); therefore, a random effect model was used for the quantitative pooling. The results revealed that high MALAT1 expression was significantly associated with lymph node metastasis (OR = 2.731; 95% CI: 1.409--5.292; *p* = 0.003). However, expression of MALAT1 was not significantly associated with gender of patients (OR = 1.748; 95% CI: 0.440--6.951; *p* = 0.428) and tumor stage T (OR = 0.501; 95% CI: 0.225--1.120; *p* = 0.092). For the XIST, we combined two studies with a total of three groups according to different clinicopathological parameters (Figure [3](#F3){ref-type="fig"}). After analysis using fixed effect model, our results revealed that high expression of XIST was significantly associated with larger tumor size (OR = 2.473; 95% CI: 1.159--5.276; *p* = 0.019). In addition, high expression of XIST was related to higher TNM stage (OR = 0.400; 95% CI: 0.184--0.868; *p* = 0.020). However, expression of XIST was not significantly associated with tumor number (OR = 0.859; 95% CI: 0.413--1.783; *p* = 0.682). Publication bias was not assessed because only two studies investigated the same lncRNA MALAT1 or XIST that were pooled into the meta-analysis.

![Forest plots of odds ratios (OR) for the association between MALAT1 expression and clinicopathological features in bladder cancer patients.](fphys-09-00652-g0002){#F2}

![Forest plots of odds ratios (OR) for the association between XIST expression and clinicopathological features in bladder cancer patients.](fphys-09-00652-g0003){#F3}

Prognosis
---------

Nineteen studies on prognosis were eligible for the final analysis, with 13/19 (68.4%) being published between 2016 and 2017. Most of the eligible studies were conducted in Chinese populations (84.2%), followed by German (5.3%), Czech (5.3%), and Netherlander (5.3%). Additionally, NOS scores indicated that 17 (89.5%) of the 19 eligible studies were not \<7 (Table [S3](#SM3){ref-type="supplementary-material"}). Summary of lncRNAs used as prognostic biomarkers of bladder cancer was presented in Table [2](#T2){ref-type="table"}. The systematic review of prognosis was performed in 1,604 patients with bladder cancer, including urinary bladder cancer, urothelial carcinoma of the bladder, muscle-invasive bladder cancer, bladder transitional cell carcinomas, and non-muscle invasive bladder cancer. Fifteen studies containing 17 lncRNAs were available to evaluate the relationship between abnormally expressed lncRNAs and OS of bladder cancer patients. HRs and their corresponding 95% CI were produced from the eligible studies. An observed HR \<1 implied that the patients with increased lncRNAs expression had a better survival. Conversely, an observed HR \> 1 implied that the patients with increased lncRNAs expression had a worse survival. Increased expressions of MALAT1 (Fan et al., [@B12]; Li et al., [@B24]), ASAP1-IT1 (Yang et al., [@B44]), SPRY4-IT1 (Zhao X. L. et al., [@B54]), TUG1 (Iliev et al., [@B23]), lncRNA-n336928 (Chen et al., [@B4]), GHET1 (Li et al., [@B25]), linc-UBC1 (He et al., [@B20]), YRNA5 (Tolkach et al., [@B35]), XIST (Hu Y. Y. et al., [@B22]), PVT1 (Cui et al., [@B5]), and SNHG16 (Cao et al., [@B2]) were significantly correlated with poor prognosis in OS, along with decreased expressions of CAT1297 (Dudek et al., [@B9]), lncRNA-LET, YRNA1 (Tolkach et al., [@B35]), YRNA3 (Tolkach et al., [@B35]), YRNA4 (Tolkach et al., [@B35]), and NBAT1 (Du et al., [@B7]). It was worth noting that the most significant association was observed between increased expressions of SPRY4-IT1 and poor OS (HR = 3.716; 95% CI: 2.084--6.719; *p* \< 0.001). One study containing 4 lncRNAs were available to evaluate the relationship between abnormally expressed lncRNAs and CSS of bladder cancer patients. Increased expressions of YRNA4 (Tolkach et al., [@B35]) and YRNA5 (Tolkach et al., [@B35]) were significantly correlated with poor prognosis in CSS, along with decreased expressions of YRNA1 (Tolkach et al., [@B35]) and YRNA3 (Tolkach et al., [@B35]). Three studies containing 3 lncRNAs were available to evaluate the relationship between abnormally expressed lncRNAs and RFS of bladder cancer patients. Increased expressions of lncRNA-UNMIBC (Zhang et al., [@B52]) and HOTAIR (Yan et al., [@B43]) were significantly correlated with poor prognosis in RFS, along with decreased expression of MEG3 (Duan et al., [@B8]). It was also worth noting that the most significant association was observed between increased expressions of HOTAIR and poor RFS (HR = 4.712; 95% CI: 2.894--8.714; *p* \< 0.001). Only one study was available to evaluate the relationship between abnormally expressed lncRNAs and DFS of bladder cancer patients. Decreased expression of GAS5 (Zhang et al., [@B51]) was significantly correlated with poor prognosis in DFS.

###### 

Summary of lncRNAs used as prognostic biomarkers of bladder cancer.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**   **Year**   **Country**      **Study design**   **Patient population**   **TNM stage**   **Treatment of patient**                                                        **LncRNAs**               **Expression**   **Number of patients**   **Number of patients**   **Detected sample**   **Detection method**   **Cutoff**   **Follow-up months**   **Survival analysis**          **HR (High vs. Low) (95% CI)**   
  ----------- ---------- ---------------- ------------------ ------------------------ --------------- ------------------------------------------------------------------------------- ------------------------- ---------------- ------------------------ ------------------------ --------------------- ---------------------- ------------ ---------------------- ------------------------------ -------------------------------- ---------------------------------------------------------
                                                                                                                                                                                                                                                          **High**                 **Low**                                                                                                                                          

  Yang L      2017       China            RCS                UBC                      I-IV            Radical cystectomy                                                              ASAP1-IT1                 Up               58                       29                       29                    Tissue                 qRT-PCR      Medium (1.42)          50 (Total)                     OS                               Multivariate: 2.639 (1.056--6.579)

  Zhang H     2017       China            PCS                BTCC                     I-III           Transurethral resection and radical cystectomy                                  GAS5                      Down             82                       41                       41                    Tissue                 qRT-PCR      NA                     60 (Total)                     DFS                              Univariate: 0.4824 (0.2865--0.8122)

  Li C        2017       China            PCS                BC                       NA              Transurethral resection of bladder tumor and radical resection of the bladder   MALAT1                    Up               120                      64                       56                    Tissue                 ISH          Mean (2.65)            60 (Total)                     OS                               Multivariate: 2.056 (1.236--3.879)

  Dudek AM    2017       Netherlands      RCS                MIBC                     NA              NA                                                                              CAT1297                   Up               121                      60                       61                    Tissue                 TCGA         NA                     168 (Total)                    OS                               Multivariate: 0.508 (0.284--0.909)

  Zhuang J    2017       China            PCS                UBC                      0-IV            Surgery                                                                         lncRNA-LET                Down             60                       30                       30                    Tissue                 qRT-PCR      Median                 60 (Total)                     OS                               Kaplan-Meier: 0.70 (0.19-- 2.57)

  Tolkach Y   2017       Germany          PCS                UBC                      NA              Transurethral resection or radical cystectomy                                   YRNA1 YRNA3 YRNA4 YRNA5   Down             88                       NA                       NA                    Tissue                 qRT-PCR      NA                     Median (range): 51 (1--210)    OS CSS                           Multivariate: OS/CSS YRNA1 0.806 (0.357--1.818)/ 0.820\
                                                                                                                                                                                                                                                                                                                                                                                                                                    (0.315--2.128) YRNA3 0.699\
                                                                                                                                                                                                                                                                                                                                                                                                                                    (0.307--1.613)/ 0.833\
                                                                                                                                                                                                                                                                                                                                                                                                                                    (0.308--2.222) YRNA4 0.926\
                                                                                                                                                                                                                                                                                                                                                                                                                                    (0.415--2.041)/ 1.111\
                                                                                                                                                                                                                                                                                                                                                                                                                                    (0.441--2.857) YRNA5 1.250\
                                                                                                                                                                                                                                                                                                                                                                                                                                    (0.617--2.564)/ 1.370\
                                                                                                                                                                                                                                                                                                                                                                                                                                    (0.556--3.333)

  Hu YY       2017       China            PCS                BC                       I-IV            Resection surgery                                                               XIST                      Up               52                       32                       20                    Tissue                 qRT-PCR      NA                     50 (Total)                     OS                               Kaplan-Meier: 1.51 (0.43--5.24)

  Du D        2017       China            RCS                BC                       NA              Surgical resection                                                              NBAT1                     Down             79                       45                       34                    Tissue                 qRT-PCR      NA                     60 (Total)                     OS                               Kaplan-Meier: 0.41 (0.14--1.17)

  Cui Y       2017       China            PCS                BC                       NA              Surgery                                                                         PVT1                      Up               146                      73                       73                    Tissue                 qRT-PCR      Mean (3.64)            60 (Total)                     OS                               Multivariate: 2.00 (1.06--3.79)

  Cao X       2017       China            PCS                BC                       0-IV            Total or partial removal of bladder                                             SNHG16                    Up               46                       25                       21                    Tissue                 qRT-PCR      Mean                   60 (Total)                     OS                               Kaplan-Meier: 2.27 (0.43--11.91)

  Iliev R     2016       Czech Republic   PCS                MIBC                     NA              Partial or radical cystectomy                                                   TUG1                      Up               47                       26                       21                    Tissue                 qRT-PCR      Mean (0.1232)          Median (range): 30 (12--104)   OS                               Multivariate: 2.54 (1.13--5.74)

  Zhang SM    2016       China            PCS                NMIBC                    NA              NA                                                                              lncRNA-UNMIBC             Up               75                       45                       30                    Tissue                 qRT-PCR      NA                     42 (Total)                     RFS                              Multivariate: 2.362 (1.504--4.837)

  Duan WL     2016       China            RCS                BC                       NA              Transurethral bladder resection or radical cystectomy                           MEG3                      Down             80                       NA                       NA                    Serum/tissue           qRT-PCR      Relative               Median (range): 57 (4--76)     RFS                              Multivariate: 0.450 (0.205--0.987)

  Zhao XL     2015       China            PCS                UCB                      NA              Transurethral resection, partial cystectomy and radical cystectomy              SPRY4-IT1                 Up               68                       38                       30                    Tissue                 qRT-PCR      Mean (3.68)            60 (Total)                     OS                               Multivariate: 3.716 (2.084--6.719)

  Chen T      2015       China            PCS                BC                       NA              Radical cystectomy                                                              lncRNA-n336928            Up               95                       44                       51                    Tissue                 qRT-PCR      NA                     60 (Total)                     OS                               Multivariate: 2.377 (1.007--5.610)

  Fan Y       2014       China            RCS                BT                       NA              NA                                                                              MALAT1                    Up               95                       45                       50                    Tissue                 qRT-PCR      Median                 30 (Total)                     OS                               Multivariate: 1.26 (0.68--2.13)

  Li LJ       2014       China            PCS                BC                       NA              Resection of the primary bladder cancer                                         GHET1                     Up               80                       39                       41                    Tissue                 qRT-PCR      Median                 60 (Total)                     OS                               Kaplan-Meier: 1.17 (0.25--5.45)

  Yan TH      2014       China            PCS                BC                       NA              Transurethral resection of the bladder                                          HOTAIR                    Up               110                      90                       20                    Tissue                 qRT-PCR      Mean                   60 (Total)                     RFS                              Multivariate: 4.712 (2.894--8.714)

  He W        2013       China            RCS                BC                       NA              Surgical resection                                                              linc-UBC1                 Up               102                      60                       42                    Tissue                 qRT-PCR      NA                     80 (Total)                     OS                               Kaplan-Meier: 1.07 (0.36--3.19)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*RCS, retrospective cohort study; PCS, prospective cohort study; UBC, urinary bladder cancer; UCB, urothelial carcinoma of the bladder; MIBC, muscle-invasive bladder cancer; BTCC, bladder transitional cell carcinomas; BC, bladder cancer; NMIBC, non-muscle invasive bladder cancer; BT, bladder tumors; LncRNAs, long non-coding RNAs; Up, up-regulation; Down, down-regulation; OS, overall survival; DFS, disease free survival; CSS, cancer-specific survival; RFS, recurrence-free survival; qRT-PCR, quantitative real-time polymerase chain reaction; ISH, in situ hybridization; TCGA, The Cancer Genome Atlas; NA, not available*.

Two studies investigated the relationship between the expression of MALAT1 and OS in a total number of 215 bladder cancer patients. Therefore, we carried out a meta-analysis on the association between abnormally expressed MALAT1 and the OS of bladder cancer patients. There was not statistically significant heterogeneity among studies (*I*~2~ = 29.9%, *p* = 0.232). After analysis using fixed effect model, our result suggested that high MALAT1 expression was significantly correlated with poor prognosis in OS (HR = 1.611; 95% CI: 1.076--2.412; *p* = 0.020) (Figure [4](#F4){ref-type="fig"}). Publication bias was not assessed because only two studies investigated the same lncRNA MALAT1 that were pooled into the meta-analysis.

![Forest plots of studies evaluating hazard ratios of up-regulated MALAT1 expression and the overall survival (OS) of bladder cancer patients.](fphys-09-00652-g0004){#F4}

Diagnosis
---------

In the diagnosis category, summary of lncRNAs used as diagnostic biomarkers of bladder cancer are presented in Table [3](#T3){ref-type="table"}. Eight lncRNAs were described in the seven studies providing complete diagnostic data. The expression of SNHG16 (Duan et al., [@B8]), MALAT1 (Duan et al., [@B8]), and UCA1 (Wang et al., [@B37]) were up-regulated in bladder cancer tissue, while the expression of YRNA1 (Tolkach et al., [@B35]), YRNA3 (Tolkach et al., [@B35]), YRNA4 (Tolkach et al., [@B35]), YRNA5 (Tolkach et al., [@B35]), and MEG3 (Duan et al., [@B8]) were down-regulated. Diagnostic accuracy differed greatly between different lncRNAs tests. We found that UCA1 test had the highest sensitivity (91.5%) and specificity (96.5%) in the study conducted by Eissa et al. (Eissa et al., [@B10]). Quality assessment of diagnostic studies included in the systematic review by the QUADAS tool was presented in Table [S4](#SM4){ref-type="supplementary-material"}, which showed that QUADAS scores of prognostic studies ranged from 9 to 12, indicating the high quality of included studies.

###### 

Summary of lncRNAs used as diagnostic biomarkers of bladder cancer.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**       **Year**   **Country**   **Study design**   **Patient population**             **TNM stage**                                            **LncRNAs**   **Expression**       **Sample size**                    **Sensitivity (%)**   **Specificity (%)**   **AUC**                                **Detected sample**                    **Detection method**                      **QUADAS (scores)^a^**             
  --------------- ---------- ------------- ------------------ ---------------------------------- -------------------------------------------------------- ------------- -------------------- ---------------------------------- --------------------- --------------------- -------------------------------------- -------------------------------------- ----------------------------------------- ------------------------ --------- ----
                                                              **Cases**                          **Controls**                                                                                                                   **Cases**             **Controls**                                                                                                                                                                     

  Tolkach Y       2017       Germany       Prospective        Bladder cancer                     Normal urothelial tissue                                 NA            YRNA1\               Down                               88                    30                    YRNA1: 90.9\                           YRNA1: 73.3\                           YRNA1: 0.851\                             Tissue samples           RT-qPCR   9
                                                                                                                                                                        YRNA3\                                                                                              YRNA3: 88.6\                           YRNA3: 80.0\                           YRNA3: 0.863\                                                                
                                                                                                                                                                        YRNA4\                                                                                              YRNA4: 75.0\                           YRNA4: 86.7\                           YRNA4: 0.844\                                                                
                                                                                                                                                                        YRNA5                                                                                               YRNA5: 75.0                            YRNA5: 73.3                            YRNA5: 0.715                                                                 

  Duan WL         2016       China         Retrospective      Bladder cancer                     Healthy and benign disease                               NA            MEG3 SNHG16 MALAT1   MEG3: Down SNHG16: Up MALAT1: Up   120                   120                   MEG3: 70.0 SNHG16: 64.2 MALAT1: 56.7   MEG3: 75.8 SNHG16: 65.0 MALAT1: 67.5   MEG3: 0.798 SNHG16: 0.687 MALAT1: 0.640   Serum/tissue samples     RT-qPCR   10

  Milowich D      2015       Belgium       Prospective        Bladder cancer                     Other urological conditions                              NA            UCA1                 Up                                 70                    92                    70.00                                  70.70                                  NA                                        Urine samples            RT-qPCR   12

  Eissa S         2015       Egypt         Retrospective      Bladder carcinoma                  Benign urological diseases                               I--III        UCA1                 Up                                 139                   45                    89.2                                   93.3                                   0.966                                     Urine samples            RT-qPCR   11

  Eissa S         2015       Egypt         Retrospective      Bladder cancer                     Benign bladder lesions and age-matched normal controls   I--III        UCA1                 Up                                 94                    116                   91.5                                   96.5                                   0.975                                     Urine samples            RT-qPCR   11

  Srivastava AK   2014       India         Retrospective      Carcinoma of the urinary bladder   Healthy individuals and non-malignant disorders          NA            UCA1                 Up                                 117                   74                    79.49                                  79.73                                  0.863                                     Urine samples            RT-qPCR   11

  Wang XS         2006       China         Retrospective      Bladder cancer                     Normal and other urinary tract disease                   NA            UCA1                 Up                                 94                    85                    80.9                                   91.8                                   0.882                                     Tissue samples           RT-qPCR   10
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*BC, Bladder cancer; LncRNAs, long non-coding RNAs; Up, up-regulation; Down, down-regulation; AUC, area under the curve; qRT-PCR, quantitative real-time polymerase chain reaction; ^a^If a cumulative score is higher than 8, the study will be considered as low risk of bias; NA, not available*.

Since five studies investigated diagnostic value of UCA1 for bladder cancer, a meta-analysis was performed based on UCA1. There was statistically significant heterogeneity in pooled sensitivity (*I*~2~ = 79.41%, *p* \< 0.01) and pooled specificity (*I*~2~ = 90.43%, *p* \< 0.01), then, a random-effect model was chosen for the generation of pooled indexes. The pooled sensitivity of UCA1 was 0.84 (95% CI: 0.76--0.89), specificity was 0.89 (95% CI: 0.78--0.95), PLR was 7.81 (95% CI: 3.45--17.68), NLR was 0.18 (95% CI: 0.11--0.30), and DOR was 39.65 (95% CI: 10.40--151.12). Forest plots of pooled sensitivity and specificity for UCA1 was presented in Figure [5](#F5){ref-type="fig"}. The AUC of SROC curve based on summary sensitivity and specificity were 0.92 (95% CI: 0.89--0.94) (Figure [6](#F6){ref-type="fig"}), indicating a moderate accuracy for the diagnostic test. To obtain the post-test probability, we performed a simulation of an environment that had a prevalence of 20% for bladder cancer, with base on the included studies. Incorporating this evidence in a Fagan\'s nomogram (Figure [7](#F7){ref-type="fig"}), it appeared that the positive post-test probability was 66% and the negative post-test probability 4%. Deeks\' funnel plot asymmetry test was performed to check publication bias in this meta-analysis. The result indicated that no significant bias was found (*t* = −0.59; *p* = 0.598). The shape of the funnel plot was presented in Figure [8](#F8){ref-type="fig"}, without any evidence of obvious asymmetry. Therefore, no obvious publication bias existed in the meta-analysis of diagnostic studies.

![Forest plot of the sensitivity (**Left**) and specificity (**Right**) of UCA1 for the diagnosis of bladder cancer.](fphys-09-00652-g0005){#F5}

![The summary receiver operator characteristic (SROC) curve based on UCA1. SECS, sensitivity; SPEC, specificity; AUC, area under the curve.](fphys-09-00652-g0006){#F6}

![Fagan\'s nomogram for the calculation of post-test probability.](fphys-09-00652-g0007){#F7}

![Funnel graph for the assessment of potential publication bias of the diagnostic studies.](fphys-09-00652-g0008){#F8}

Discussion {#s4}
==========

Increasing evidences have indicated that abnormally expressed lncRNAs were correlated with clinical outcomes for patients with bladder cancer in recent years. Multiple lncRNAs were highlighted as potential diagnostic and prognostic biomarkers for bladder cancer and shown to be potential new targets for cancer drugs. Eissa et al. ([@B11]) found that there was a significant difference between bilharzial benign and malignant cases regarding urinary lncRNA-UCA1 expression, and suggested that UCA1-nanoassay was a valid test for direct detection of urine UCA1 for bladder cancer detection. Fan et al. ([@B12]) revealed that MALAT1 level was higher in primary tumors that subsequently metastasized than those in non-metastatic bladder cancer, and suggested that MALAT1 inhibition may represent a promising therapeutic option for suppressing bladder cancer progression. While Li et al. ([@B24]) demonstrated that high tumor stage, positive lymph nodes, and high MALAT1 expression were independent prognostic indicators for OS of bladder cancer patients, and suggested that high MALAT1 expression could be considered as a potential therapeutic target of bladder cancer. However, most studies examining the clinical values of aberrantly expressed lncRNAs was limited by relatively small sample size or single lncRNA, which may result in inconsistent biological conclusions. Therefore, we performed a comprehensive systematic review and meta-analysis to systematically evaluate the clinical values of various lncRNAs in bladder cancer.

In the present systematic review, we investigated the relationship between multiple lncRNAs and clinicopathological parameters of bladder cancer. Most of the included studies suggested that multiple lncRNAs might be used as potential biomarkers of histological grade, TNM stage, tumor stage T, and lymph node metastasis. Many lncRNAs were identified in multiple different studies but only 2 (MALAT1 and XIST) were found to be studied in more than one study. For the MALAT1, Li et al. ([@B24]) reported that high expression of MALAT1 was closely associated with higher probability of lymph node metastasis; but Fan et al. ([@B12]) did not find statistically significant association between increased MALAT1 expression and lymph node metastasis. Pooled result showed that high expression of MALAT1 was significantly associated with lymph node metastasis, suggesting that MALAT1 can serve as a valuable biomarker for predicting lymph node metastasis status. For the XIST, high expression of XIST was related to larger tumor size and higher TNM stage after we pooled OR, suggesting that XIST can serve as a valuable biomarker for predicting tumor size and TNM stage in patients with bladder cancer. However, we did not provide enough information about bladder cancer patients. Some studies reported that patients were treated by surgery only and did not receive radiotherapy, chemotherapy, or other therapy before surgery; others did not mention treatment. Clinicopathological data such as gender, age, histological grade, TNM stage, or lymph nodal status were obtained at the same time. TNM stage was reported only in some studies and ranged from 0 to IV. LncRNAs expression was detected using by quantitative real-time PCR in tissue sample which were obtained and immediately frozen at the same time. Then study evaluated the association between lncRNAs and clinicopathological parameters. So whether the patients can be cured was not reported in the most studies included.

We explored the prognostic role of multiple lncRNAs in bladder cancer. For OS, we found that the increased expressions of 11 lncRNAs were related to poor prognosis in bladder cancer, while the decreased expressions of 6 lncRNAs were related to poor prognosis. Among them, SPRY4-IT1 (Zhao X. L. et al., [@B54]) exhibited the highest HR of 3.72, while NBAT1 (Du et al., [@B7]) exhibited the lowest HR of 0.41. Meta-analysis of different lcRNAs with prognosis was not performed, because we thought that meta-analysis of random lcRNAs doesn\'t make sense on a scientific level. However, MALAT1 was investigated in two studies (Fan et al., [@B12]; Li et al., [@B24]), so we carried out a meta-analysis on the association between abnormally expressed MALAT1 and the OS of bladder cancer patients. Our result suggested that high expression of MALAT1 was significantly correlated with poor prognosis in OS among patients with bladder cancer. A previous meta-analysis conducted by Tian and Xu ([@B33]) reported that MALAT1 expression was an independent prognostic marker for OS in patients with cancer using univariate and multivariate analyses, those findings in consist with our results. Therefore, high MALAT1 expression can serve as an independent prognostic factor for OS of bladder cancer patients and can be considered as a potential therapeutic target of bladder cancer.

Diagnostic accuracy of multiple lncRNAs tests was explored in the present systematic review. Different lncRNAs tests differed in their sensitivity and specificity. Five studies investigated diagnostic value of lncRNA UCA1 for bladder cancer, but diagnostic accuracy differed greatly among these studies. Meta-analysis is a method of summarizing discrepant data on the accuracy of diagnostic tests. So a meta-analysis was performed based on UCA1. As a result, the overall pooled sensitivity and specificity of UCA1 for bladder cancer were 0.84 and 0.89, respectively, along with an AUC value of 0.92, suggesting that the diagnostic accuracy of UCA1 was moderate. However, there was statistically significant heterogeneity in pooled sensitivity and pooled specificity. We supposed that the patient populations, sample size, and the different cut-off value might be the potential source. But data were not enough to illustrate main source of heterogeneity. Thus, a meta-regression analysis is urgently needed to assess how study-specific attributes caused heterogeneity. The DOR shows the correlation between diagnostic efficiency and the disease, which has better discriminatory test performance with an extremely higher value (Glas et al., [@B14]). In current study, the DOR value was calculated to be 39.65, suggesting a moderate diagnostic accuracy of UCA1 for bladder cancer diagnosis. In addition, a lower NLR and a higher PLR values show a better diagnostic performance. In this study, the pooled PLR and NLR values were calculated to be 7.81 and 0.18 for UCA1, respectively, also suggesting a moderate diagnostic accuracy. These data suggested that UCA1 expression test showed a moderate diagnostic accuracy for bladder cancer. Therefore, UCA1 can be considered as a potential biomarker to assist in the diagnosis of bladder cancer. The diagnostic significance of UCA1 expression in bladder cancer has been investigated by meta-analysis in recent studies (Wang Z. et al., [@B38]; Zhen et al., [@B55]). Compared with a previous meta-analysis (Wang Z. et al., [@B38]), we found that there was similar sensitivity, but there was slightly higher specificity, DOR, and AUC in our results. The different in results may be due to the fact that non-English papers were excluded from our meta-analysis.

There are several limitations in our systematic review. Firstly, most of the included studies were conducted in Chinese populations, so the conclusion of this study might not be extended to all populations. Secondly, mutiple lncRNAs were used to evaluate the clinicopathological parameters, prognosis, and diagnosis of bladder cancer, so we may overestimate the clinical values of single lncRNA. Thirdly, HR and its 95% CI were extracted from Kaplan--Meier survival curves in seven studies, which may be less reliable than those directly acquired from survival data. Finally, although our searches were extensive and were not limited by language, language bias should not be completely avoided because of all included studies written in English.

In conclusion, systematic review elaborated that abnormal lncRNAs expression can serve as potential markers for prognostic evaluation in bladder cancer patients. More importantly, the diagnostic meta-analysis concluded that abnormally expressed UCA1 can function as potential diagnostic markers for bladder cancer. However, most lncRNAs were investigated in a single study, whose results were not enough to illustrate the clinical value of lncRNAs completely. So larger-size and higher-quality studies need to be conducted to validate the clinical value of single lncRNA in patients with bladder cancer.
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